Hims & Hers Health (NYSE:HIMS) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Hims & Hers Health (NYSE:HIMS) released its quarterly earnings results on Monday. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.01, Briefing.com reports. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. During the same period in the previous year, the company posted ($0.03) earnings per share. The firm’s revenue was up 51.8% on a year-over-year basis.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded down $0.69 during midday trading on Tuesday, reaching $17.15. 11,352,575 shares of the company’s stock traded hands, compared to its average volume of 7,732,266. The company has a market cap of $3.68 billion, a price-to-earnings ratio of -1,628.00 and a beta of 1.08. Hims & Hers Health has a one year low of $5.65 and a one year high of $25.74. The stock has a 50 day moving average of $21.39 and a 200 day moving average of $15.80.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $19.88, for a total transaction of $3,755,093.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $19.88, for a total transaction of $3,755,093.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Chi sold 7,500 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $24.50, for a total value of $183,750.00. Following the sale, the insider now owns 185,326 shares of the company’s stock, valued at approximately $4,540,487. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 782,901 shares of company stock worth $16,138,997. 17.71% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on HIMS shares. Truist Financial lifted their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Jefferies Financial Group boosted their target price on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Bank of America boosted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, Canaccord Genuity Group boosted their target price on Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Seven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.07.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.